Result for
Tag: vaccines
October 1, 2020
Expert Forecasts of COVID-19 Vaccine Development Timelines
Among 28 vaccine experts (20 Canada, 6 US) with 25 median years of experience working with vaccines (range 8–42), 53% said the pace of COVID-19 research is increasing the potential for errors. The median probability forecast that a vaccine would receive a black box warning label for a widely deployed vaccine was 30% and that…
September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults
A phase 1, dose escalation trial of a messenger RNA vaccine against SARS-CoV-2 conducted among adults ages 56-70 (n=20) and ages 71 or older (n=20) reported generating antibody response with mild to moderate adverse events. Serum neutralizing activity was detected in all participants and was similar in magnitude to responses previously reported among participants between…
September 25, 2020
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
[Pre-print, not peer reviewed] A one-dose vaccine candidate was shown to have an acceptable safety profile and demonstrated immunogenicity. These results come from a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study of the Ad26.COV2.S vaccine candidate. The vaccine platform utilizes Janssen Pharmaceutical’s replication incompetent adenovirus serotype 26 (Ad26) 54 vector and includes a stabilized…
September 23, 2020
Optimal Dynamic Prioritization of Scarce COVID-19 Vaccines
[Pre-print, not peer-reviewed] A modeling study reported that prioritizing a limited supply of SARS-CoV-2 vaccines to certain population groups resulted in 17-18% fewer deaths, infections, and years of life lost compared to a non-prioritized strategy. The optimal strategies consistently prioritized older essential workers, though the model allowed the priority groups to vary over time. Optimal…
September 10, 2020
Demographic Differences in US Adult Intentions to Receive a Potential Coronavirus Vaccine and Implications for Ongoing Study
[Pre-print, not peer reviewed] A cross-sectional survey of US adults (n=1000) collected in May 2020 found that nearly 50% of respondents either planned not to receive a COVID-19 vaccine or were unsure, signaling potential problems with vaccine uptake. Higher likelihood of intention to receive the vaccine versus uncertainty and refusal was more common among respondents…
August 31, 2020
Acceptability of a COVID-19 Vaccine among Adults in the United States: How Many People Would Get Vaccinated?
Sixty-nine percent of respondents to an online survey targeting American adults (n=2,006) were willing to get a COVID-19 vaccine. Participants were more likely to get vaccinated if they thought their healthcare provider would recommend vaccination (RR=1.73) or if they described their political affiliation as moderate (RR=1.09) or liberal (RR=1.14) compared to people who identified as…
August 20, 2020
Factors Determining COVID-19 Pneumonia Severity in a Country with Routine BCG Vaccination
• A retrospective cross-sectional study among 123 adults with COVID-19 in Istanbul, Turkey found that the patients with severe disease were less likely to have had a BCG vaccination than patients with mild disease (69% vs 88%), but after adjustment for factors associated with COVID-19 severity, BCG vaccination was not associated with the disease severity….
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
• [Preprint, not peer-reviewed] Walsh et al. report Phase 1 results of an ongoing dose-escalation clinical trial of two RNA vaccine candidates for SARS-CoV-2 (BNT162b1 and BNT162b2) among 195 healthy adults randomized into 13 groups based on age (18-55 or 65-85 years), vaccine type and vaccine dose. Participants received two injections of either vaccine or…
Previous page